CJC-1295 without DAC vs AOD9604 (Fragment 176-191): what the research compares
A research-facing comparison of CJC-1295 without DAC and AOD9604 (Fragment 176-191): compound classes, the models and endpoints published work has measured, where the evidence base is denser for one agent, and which ques
CJC-1295 without DAC is a growth hormone-releasing hormone (GHRH) analogue, also written as CJC-1295 (no DAC) or modified GRF(1-29); it belongs to the GHRH analogue class of peptides and is grouped in the literature alongside sermorelin and tesamorelin as an agent intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis [1]. AOD9604 (Fragment 176-191) is the growth hormone fragment hGH 176-191, also catalogued as Anti-Obesity Drug 9604, and is listed in the same review literature as a distinct entry from the GHRH analogues and the growth hormone secretagogues [1][4].
The published work on both compounds centres on the GH-IGF-1 axis and its downstream metabolic and tissue-repair endpoints, with CJC-1295 without DAC positioned as a GHRH-receptor-directed secretagogue and AOD9604 positioned as a GH fragment studied for metabolic rather than somatotropic activity [1][3].
Research Studies
CJC-1295 without DAC and the GH-IGF-1 axis
Review coverage of performance-enhancing peptides places CJC-1295 without DAC within the GHRH analogue group, a set of agents described as intended to modulate the GH-IGF-1 axis and encountered both in clinical practice and in online self-administration protocols [1]. The same review lists CJC-1295 with Drug Affinity Complex (DAC) as a separate entry from CJC-1295 without DAC, indicating that the two are treated as distinct research subjects rather than interchangeable ones [1].
CJC-1295 and HIV-associated visceral obesity
A multicentre, randomized, placebo-controlled, double-blind Phase 2 study was registered to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity [6]. Participants were treated for a total of 12 weeks with a 6-week follow-up period after treatment ended, and were randomly assigned to low dose CJC 1295, high dose CJC 1295, or placebo [6]. This is the most specific human trial record in the evidence set for either compound.
AOD9604 (Fragment 176-191) and the GH fragment class
AOD9604 is described in the sports-medicine peptide literature as AOD-9604 (Anti-Obesity Drug 9604), presented alongside other approved and unapproved peptides marketed direct to patients, with attention to pharmacological mechanisms, safety profiles, and regulatory status [4][5]. The gerontology review literature treats therapeutic peptides as an emerging frontier targeting hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline, which is the framing in which a GH fragment studied for metabolic endpoints sits [3].
CJC-1295 without DAC and AOD9604 in the same review literature
Both compounds appear in a single review of performance-enhancing peptides marketed as “research compounds,” which lists GHRH analogues (sermorelin, tesamorelin, CJC-1295 with DAC, CJC-1295 without DAC), growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD9604 (hGH 176-191), and an IGF-1 analogue as the agents most commonly encountered [1]. That co-listing is the clearest published statement that the two are studied as separate classes within one axis, not as variants of one another [1].
Purity and measured abundance in research-grade peptide supply
An evaluation of research-grade peptides marketed directly to consumers assessed purity, measured abundance, and endotoxin burden using a large publicly available independent testing dataset, and compared cost against compounded and FDA-approved alternatives [2]. The study frames peptides as a rapidly expanding drug class with a parallel, largely unregulated gray market sold directly to consumers for self-administration, and notes reported uses including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement [2]. This work addresses the supply chain rather than the pharmacology of either compound.
CJC-1295 without DAC and AOD9604 in sports-medicine peptide reviews
Structured narrative review work on injectable peptides in sports medicine reports that clinical adoption has outpaced high-quality evidence and regulatory consensus, and sets out to summarize contemporary human and translational evidence [8]. Related review work on peptide supplements in sports medicine notes that these products are often perceived as low risk despite the absence of efficacy and safety data [7]. A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes the shift from anabolic-androgenic steroids toward peptides marketed as more selective and ostensibly safer alternatives [10].
Where the evidence is stronger for CJC-1295 without DAC
The evidence set contains a registered randomized, placebo-controlled, double-blind Phase 2 trial with defined dosing arms, a 12-week treatment period, and a 6-week follow-up in a named population — patients with HIV-associated visceral obesity — for CJC 1295 [6]. No comparable registered trial record appears in the evidence set for AOD9604. On that basis, the human trial infrastructure described in this evidence is denser for CJC-1295 than for AOD9604.
Where the evidence is stronger for AOD9604 (Fragment 176-191)
AOD9604 is named explicitly and repeatedly in the sports-medicine review literature as a prominent unapproved peptide marketed direct to patients, with its pharmacological mechanism, safety profile, and regulatory status discussed under that heading [4][5]. It is also named in the performance-enhancing peptide review as the GH fragment entry, distinct from the GHRH analogues and secretagogues [1]. The evidence set does not contain an equivalent named treatment section for CJC-1295 without DAC in those same reviews.
What is not known from this evidence
No head-to-head study comparing CJC-1295 without DAC against AOD9604 (Fragment 176-191) appears in the evidence set. No sequence, molecular formula, or molecular weight is given for either compound in the evidence provided here. No human efficacy endpoint data are reported for AOD9604 in this evidence, and no results are reported for the registered CJC 1295 trial beyond its design and objectives [6]. The review literature states that clinical adoption of injectable peptides has outpaced high-quality evidence and regulatory consensus, and that efficacy and safety data are absent for many marketed peptides [7][8].
Comparison summary
| Feature | CJC-1295 without DAC | AOD9604 (Fragment 176-191) |
|---|---|---|
| Class as listed in review literature | GHRH analogue [1] | GH fragment, hGH 176-191 [1] |
| Synonyms in evidence | CJC-1295 (no DAC); listed separately from CJC-1295 with DAC [1] | AOD-9604; Anti-Obesity Drug 9604 [4][5] |
| Axis or pathway framing | GH-IGF-1 axis modulation [1] | GH fragment class; metabolic and aging-hallmark framing [1][3] |
| Registered human trial in evidence | Phase 2, randomized, placebo-controlled, double-blind, 12 weeks treatment, 6 weeks follow-up, HIV-associated visceral obesity [6] | None in this evidence set |
| Named in sports-medicine review sections | Not named in the sections available here | Named as a prominent unapproved peptide marketed direct to patients [4][5] |
| Supply-chain data | Covered by general research-grade peptide purity and abundance evaluation [2] | Covered by general research-grade peptide purity and abundance evaluation [2] |
| Head-to-head data | None in this evidence set | None in this evidence set |
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis — https://europepmc.org/article/PMC/PMC13322892
- [2] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — https://doi.org/10.20944/preprints202604.1748.v1
- [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
- [4] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
- [6] A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity — https://clinicaltrials.gov/study/NCT00267527
- [7] Peptide Supplements and Their Therapeutic Applications in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
- [8] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — https://pubmed.ncbi.nlm.nih.gov/42160466/
- [9] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/
- [10] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — https://pubmed.ncbi.nlm.nih.gov/41880199/